• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Paranovus Entertainment Technology Ltd.

    7/6/26 4:15:09 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $PAVS alert in real time by email
    6-K 1 pavs_6k.htm FORM 6-K pavs_6k.htm

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of July 2026

     

    Commission File Number: 001-39098

     

    PARANOVUS ENTERTAINMENT TECHNOLOGY LTD.

     

    1177 6th Avenue, Floor 5

    New York, NY 10036

    (Address of Principal Executive Office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

     

    Form 20-F ☒     Form 40-F ☐

     

     

     

      

    Change in Registrant’s Certifying Accountant

     

    On June 26, 2026, of the audit committee (the “Committee”) of the board of directors (the “Board”) of Paranovus Entertainment Technology Ltd.’s (the “Company”), has resolved to accept the resignation of HHL LLP (the “Former Auditor”) as the Company’s independent registered public accounting firm, effective on June 26, 2026, and to appoint HCL, PLLC (the “New Auditor”) to serve as its independent registered public accounting firm, effective on June 26, 2026.

     

    Since the Former Auditor’s appointment on October 19, 2025 and up to June 26, 2026, the Former Auditor has not issued any report on the financial statements of the Company and has neither provided any adverse opinion or qualifications on the Company’s financial statements nor had a disagreement with the Company since their engagement on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements that, if not resolved to the Former Auditor’s satisfaction, would have caused the Former Auditor to make reference to the subject matter thereof in its reports for such fiscal years and interim period.

     

    During the two most recent fiscal years ended March 31, 2026 and 2025, and through the subsequent interim period preceding the release, there was no “reportable event” within the meaning of Item 16F(a)(1)(v) of Form 20-F.

     

    The Company has provided the Former Auditor with a copy of this report prior to its filing with the U.S. Securities and Exchange Commission (the “SEC”). The Former Auditor has provided a letter to us, dated June 26, 2026 and addressed to the SEC, which is attached hereto as Exhibit 16.1 and is hereby incorporated herein by reference.

     

    During the two most recent fiscal years ended March 31, 2026 and 2025, and any subsequent interim periods prior to the engagement of the New Auditor, neither the Company, nor someone on behalf of the Company, has consulted New Auditor regarding (i) the application of accounting principles to any specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company’s financial statements; (ii) the type of audit opinion that might be rendered on the Company’s financial statements by the New Auditor in either case where written or oral advice provided by the New Auditor would be an important factor considered by the Company in reaching a decision as to any accounting, auditing or financial reporting issues; or (iii) any matter that was either the subject of a disagreement (as defined in paragraph (a)(1)(iv) of Item 304 of Regulation S-K and the related instructions thereto) or a reportable event (as described in paragraph (a)(1)(v) of Item 304 of Regulation S-K).

     

    Entry Into Material Definitive Agreements

     

    On June 30, 2026, the Company, entered into a securities purchase agreement (the “Securities Purchase Agreement”) with Happy Group Inc., a Cayman Islands company and an existing shareholder of the Company, which is wholly owned by the Company’s Chairwoman of the board of directors, Minzhu Xu (“Affiliate”). Pursuant to the Securities Purchase Agreement, the Affiliate agreed to subscribe for and purchase from the Company, and the Company agreed to issue and sell to the Affiliate, an aggregate of 12,500 Class B ordinary shares of the Company, par value US$0.0012 per share (“Class B Ordinary Shares”), for a purchase price of US$8.00 per share, representing 130% of the closing price of the Class A ordinary shares of the Company, par value $0.0012 each (“Class A Ordinary Shares”, collectively with Class B Ordinary Shares, the “Ordinary Shares”), as of June 29, 2026, as reported on Nasdaq.com. The gross proceeds from this offering are $100,000. The 12,500 Class B Ordinary Shares are issued in accordance with Regulation S under the Securities Act of 1933, as amended.

     

    The transaction contemplated by the Securities Purchase Agreement was closed on July 2, 2026. The entry into the Securities Purchase Agreement and the consummation of the transaction contemplated thereby have been approved by the Company’s audit committee of the board of directors on June 30, 2026.

     

    Immediately following the closing of the transaction contemplated by the Securities Purchase Agreement, Minzhu Xu, through Happy Group Inc., beneficially owns 4 Class A Ordinary Shares and 12,739 Class B Ordinary Shares, representing approximately 54.32% of the aggregate voting power of the Company’s outstanding Ordinary Shares.

     

    The foregoing summary of the Securities Purchase Agreement is subject to, and qualified in its entirety by, such document. A copy of the Securities Purchase Agreement is attached hereto as Exhibit 10.1 and is incorporated herein by reference.

     

     

    2

     

       

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

    Paranovus Entertainment Technology Limited

     

     

    Date: July 6, 2026

    By:

    /s/ Xiaoyue Zhang

     

    Name:

    Xiaoyue Zhang

     

    Title:

    Chief Executive Officer

     

     

     

    3

     

      

    EXHIBIT INDEX

     

    Exhibit No.

     

    Description

    10.1

     

    Securities Purchase Agreement dated June 30, 2026 by and between Paranovus Entertainment Technology Group LTD and Happy GROUP Inc

    16.1

     

    Letter from HHL LLP to the U.S. Securities and Exchange Commission, dated June 26, 2026

     

     

      

    Get the next $PAVS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PAVS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PAVS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PAVS Announces Pricing of a $10 Million Registered Direct Offering of Class A Ordinary Shares and Pre-Funded Warrants

    NEW YORK, June 15, 2026 (GLOBE NEWSWIRE) -- PAVS (NASDAQ:PAVS) (the "Company"), a consumer products and digital commerce solutions company, today announced that it has entered into a definitive agreement with certain institutional investors for a registered direct offering of an aggregate of 50,000,000 Class A ordinary shares (or pre-funded warrants to purchase Class A ordinary shares in lieu thereof) at a purchase price of $0.20 per share. The gross proceeds to the Company from the offering are expected to be approximately $10 million, before deducting offering expenses. The offering is expected to close on or about June 16, 2026, subject to the satisfaction of customary closing conditio

    6/15/26 2:30:00 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    Beyond Fast Fashion: Advanced Fibers and Smart Manufacturing Are Reshaping the Global Textile Industry

    DENVER, June 15, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – The textile and apparel sector is rarely considered one of the market's most exciting industries. Yet some of today's most intriguing innovation stories are emerging from companies seeking to transform how fabrics are produced, sourced, and utilized across global supply chains. From recombinant spider silk to direct-to-consumer activewear brands and expanding manufacturing capacity, a new generation of companies is positioning itself around themes that include sustainability, performance materials, advanced manufacturing, and next-generation consumer products. Investors searching for emerging opportunities are increasingl

    6/15/26 10:36:44 AM ET
    $GIII
    $JRSH
    $PAVS
    Apparel
    Consumer Discretionary
    Medicinal Chemicals and Botanical Products
    Health Care

    Paranovus Entertainment Technology Limited Announces Pricing of $5 Million Registered Direct Offering At-The-Market Under NASDAQ Rules

    NEW YORK, March 24, 2026 /PRNewswire/ -- Paranovus Entertainment Technology Limited (NASDAQ:PAVS) today announced that it has entered into a definitive agreement with a single institutional investor for a registered direct offering priced at-the-market under Nasdaq Rules of an aggregate of 14,285,715 Class A ordinary shares (or Class A ordinary share equivalents in lieu thereof) at a purchase price of $0.35 per share. The gross proceeds to the Company from the offering are expected to be approximately $5 million, before deducting placement agent commissions and other offering expenses. The offering is expected to close on or about March 25, 2026, subject to the satisfaction of customary clos

    3/24/26 3:09:00 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    $PAVS
    SEC Filings

    View All

    SEC Form 6-K filed by Paranovus Entertainment Technology Ltd.

    6-K - Paranovus Entertainment Technology Ltd. (0001751876) (Filer)

    7/6/26 4:15:09 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by Paranovus Entertainment Technology Ltd.

    6-K - Paranovus Entertainment Technology Ltd. (0001751876) (Filer)

    6/16/26 4:15:23 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 424B5 filed by Paranovus Entertainment Technology Ltd.

    424B5 - Paranovus Entertainment Technology Ltd. (0001751876) (Filer)

    6/16/26 12:45:38 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    $PAVS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Xu Minzhu

    3 - Paranovus Entertainment Technology Ltd. (0001751876) (Issuer)

    4/6/26 2:07:10 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 3 filed by new insider Xu George Yijian

    3 - Paranovus Entertainment Technology Ltd. (0001751876) (Issuer)

    3/20/26 2:23:50 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 3 filed by new insider Guo Ling

    3 - Paranovus Entertainment Technology Ltd. (0001751876) (Issuer)

    3/20/26 2:23:24 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    $PAVS
    Financials

    Live finance-specific insights

    View All

    Paranovus Entertainment Technology Limited Regains Compliance with Nasdaq Minimum Bid Price Requirement

    NEW YORK, Jan. 9, 2026 /PRNewswire/ -- Paranovus Entertainment Technology Limited (NASDAQ:PAVS) today announced that on January 6, 2026, it received notification from the Nasdaq Office of General Counsel stating that the Company had regained compliance with the bid price requirement as set forth in Listing Rule 5550(a)(2) and that Company is therefore in compliance with the Nasdaq Capital Market's listing requirements. As a result, the scheduled hearing before the Hearings Panel on January 29, 2026 had been cancelled and the matter was closed. The Company's Class A ordinary shares will continue to be listed and traded on The Nasdaq Capital Market under the ticker "PAVS."

    1/9/26 8:45:00 AM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    Paranovus Entertainment Technology Limited Received Nasdaq Delisting Notice

    NEW YORK, Dec. 22, 2025 /PRNewswire/ -- Paranovus Entertainment Technology Limited (NASDAQ:PAVS), announced today that the Company received a letter from the Nasdaq Stock Market LLC ("Nasdaq") on December 17, 2025, notifying the Company that the Nasdaq staff has determined to delist the Company's Class A ordinary shares from The Nasdaq Capital Market, because the Company failed to comply with the Nasdaq Listing Rule 5810(c)(3)(A)(iii) (the "Rule"). As previously disclosed, on July 11, 2025, the Nasdaq staff notified the Company that the bid price of its listed Class A ordinary

    12/22/25 4:30:00 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    Paranovus Entertainment Technology Limited Announces 1-For-100 Reverse Share Split

    NEW YORK, Dec. 16, 2025 /PRNewswire/ -- Paranovus Entertainment Technology Limited (NASDAQ:PAVS), today announced that it will effect a reverse share split of its outstanding Class A ordinary shares, par value $0.01 per share (the "Class A Ordinary Shares"), at a ratio of 1-for-100, to be effective at the open of business on Thursday, December 18, 2025. Our Class A Ordinary Shares will begin trading on a reverse share split-adjusted basis at the opening of The Nasdaq Capital Market ("Nasdaq") on Thursday, December 18, 2025. Following the reverse share split, the Class A Ordina

    12/16/25 9:00:00 AM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    $PAVS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Paranovus Entertainment Technology Ltd.

    SC 13G - Paranovus Entertainment Technology Ltd. (0001751876) (Subject)

    11/26/24 12:56:47 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G filed by Paranovus Entertainment Technology Ltd.

    SC 13G - Paranovus Entertainment Technology Ltd. (0001751876) (Subject)

    11/26/24 12:56:31 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G filed by Paranovus Entertainment Technology Ltd.

    SC 13G - Paranovus Entertainment Technology Ltd. (0001751876) (Subject)

    11/26/24 12:55:36 PM ET
    $PAVS
    Medicinal Chemicals and Botanical Products
    Health Care